Want to see IN:INNOVACAP full AI Analyst Report?
INNOVACAP Stock Chart & Stats
₹957.45
₹7.35(0.77%)
At close: 4:00 PM EDT
₹957.45
₹7.35(0.77%)
Day’s Range― - ―
52-Week Range₹608.25 - ₹1,350.05
Previous CloseN/A
Volume8.81K
Average Volume (3M)69.16K
Market Cap
₹56.34B
Enterprise Value₹42.05B
Total Cash (Recent Filing)₹682.50M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)36.7
Beta0.78
Next Earnings
Nov 06, 2026Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)26.91
Shares Outstanding57,224,930
10 Day Avg. Volume4,238
30 Day Avg. Volume69,163
Financial Highlights & Ratios
PEG Ratio2.83
Price to Book (P/B)3.62
Price to Sales (P/S)2.46
P/FCF Ratio114.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)33.05
Revenue Forecast (FY)₹20.19B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthStrong revenue expansion indicates effective market execution and growing demand for the company’s pharmaceutical manufacturing and finished-dose offerings. If sustained, this scale can improve operating leverage, support investment in capacity and development, and strengthen customer relationships over the next several quarters.
Solid ProfitabilityHealthy operating and net margins, together with rising net income, show that growth is translating into meaningful earnings rather than only expanding sales. This profitability provides internal funding for product development, production capabilities and customer programs while supporting resilience across the business cycle.
Improving LeverageImproving debt-to-equity and a larger equity base enhance financial flexibility as the company expands its asset base. Manageable leverage reduces balance-sheet strain, supports continued investment in manufacturing and formulation capabilities, and gives management greater room to fund growth without excessive reliance on debt.
Bears Say
Weak Free Cash FlowRepeatedly negative free cash flow indicates that reported growth has required substantial reinvestment and/or working-capital funding. Although 2026 turned modestly positive, limited surplus cash can constrain self-funded expansion, reduce capital-allocation flexibility and increase dependence on financing if investment needs remain high.
Low Cash ConversionOperating cash flow that trails reported earnings raises questions about the timing and quality of earnings conversion. Persistent weakness would limit the company’s ability to convert pharmaceutical sales into deployable funds, making it harder to finance growth, reduce debt or withstand operational volatility internally.
Gross Margin VolatilityThe decline in gross margin suggests that product mix, pricing or cost pressures may be offsetting part of the benefit from rapid revenue growth. If this volatility persists, it could reduce operating leverage, limit earnings scalability and make future profitability more sensitive to the composition of sales.
Innova Captab Limited News
INNOVACAP FAQ
What was Innova Captab Limited’s price range in the past 12 months?
Innova Captab Limited lowest stock price was ₹608.25 and its highest was ₹1350.05 in the past 12 months.
What is Innova Captab Limited’s market cap?
Innova Captab Limited’s market cap is ₹56.34B.
When is Innova Captab Limited’s upcoming earnings report date?
Innova Captab Limited’s upcoming earnings report date is Nov 06, 2026 which is in 11 days.
How were Innova Captab Limited’s earnings last quarter?
Innova Captab Limited released its earnings results on Aug 11, 2026. The company reported ₹7.7 earnings per share for the quarter, beating the consensus estimate of ₹3.4 by ₹4.3.
Is Innova Captab Limited overvalued?
According to Wall Street analysts Innova Captab Limited’s price is currently Overvalued.
Does Innova Captab Limited pay dividends?
Innova Captab Limited pays a Notavailable dividend of ₹2 which represents an annual dividend yield of 0.2%. See more information on Innova Captab Limited dividends here
What is Innova Captab Limited’s EPS estimate?
Innova Captab Limited’s EPS estimate is 8.
How many shares outstanding does Innova Captab Limited have?
Innova Captab Limited has 57,224,930 shares outstanding.
What happened to Innova Captab Limited’s price movement after its last earnings report?
Innova Captab Limited reported an EPS of ₹7.7 in its last earnings report, beating expectations of ₹3.4. Following the earnings report the stock price went up 5.494%.
Which hedge fund is a major shareholder of Innova Captab Limited?
Currently, no hedge funds are holding shares in IN:INNOVACAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Innova Captab Limited
Innova Captab Limited, established in Panchkula, India, in 2005, operates as a comprehensive pharmaceutical enterprise. Its operations encompass the full spectrum of drug development, from research and development and manufacturing to distribution and marketing, serving both domestic and international markets. The company also extends Contract Development and Manufacturing Organization (CDMO) services to other pharmaceutical businesses within India. Furthermore, Innova Captab is actively involved in developing, producing, and supplying a diverse array of generic medications. These formulations address a broad range of therapeutic areas, including anti-infectives (such as cephalosporins and antivirals), gastrointestinal treatments (like proton pump inhibitors and antiemetics), pain and inflammation management (including NSAIDs and analgesics), respiratory and allergy relief, cardiovascular support, antidiabetics, various neurological and psychiatric therapies, and solutions for urological conditions, among numerous other specialized segments. These pharmaceutical offerings are provided in multiple forms, such as tablets, capsules, dry syrups, injectable powders, ointments, and liquid oral preparations. Innova Captab distributes its branded generic products through an extensive network of distributors and pharmacies, in addition to utilizing various online e-commerce pharmacy platforms.
Technical Analysis
Bliss Gvs Pharma Limited
―
Gufic Biosciences Limited
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―
Unichem Laboratories Limited
―